Brilinta
utilized to manage acute coronary syndrome to mitigate platelet activity.
Strengths: 60 · 90mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Brilique
- Therapeutic class
Platelet Aggregation Inhibitor
- Pharmacological class
P2Y12 Receptor Antagonist
- Contraindications
active bleeding; history of intracranial haemorrhage; severe hepatic impairment
- Precautions and warnings
risk of bleeding; inform medical staff before surgery; monitor for dyspnoea
- Minor side effects
dyspnoea; bruising
- Moderate side effects
epistaxis; gastrointestinal haemorrhage
- Serious side effects
intracranial haemorrhage — requires immediate medical attention
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
utilized to manage acute coronary syndrome to mitigate platelet activity.
- Prescription status
POM
- Manufacturer
AstraZeneca
- Onset Time
30–60 minutes
- Duration
12 hours
- Storage instructions
Store below 30°C.
- Drug interactions
aspirin; clopidogrel; ketoconazole
- Pregnancy and breastfeeding
Pregnancy: not recommended. Breastfeeding: not recommended.
Mechanism of action
Reduces the risk of clots by inhibiting the P2Y12 platelet receptor, thereby reducing platelet aggregation.
Brilinta
utilized to manage acute coronary syndrome to mitigate platelet activity.
Editorial Notes
- Active ingredient(s): Ticagrelor
- Listed indication(s): Acute Coronary Syndrome
Usually available as
- 84 tablets - 60 mg1497-60-mg-17879
- 56 tablets - 90 mg1497-90-mg-17884